News for January 2018

The Current issue of “The view from here” is concerned with Medicinal Chemistry

The topic of this month’s newsletter from Drug Discovery Today is “Medicinal Chemistry””.
26 January, 2018

Drug trial protocol redactions by industry sponsors exposed

Trial protocols are needed for a proper assessment of the veracity of drug trial reports. The researchers, from the Nordic Cochrane Centre in Copenhagen, found widespread redactions in the protocols for commercially sponsored trials they received from research ethics committees in Denmark. The study is believed to be the first systematic assessment of which information in trial protocols pharmaceutical companies do not wish to disclose to independent researchers.
26 January, 2018

New report reveals UK has the strongest R&D pipeline in Europe and the UK sector is maturing

‘Pipeline Progressing: the UK’s global bioscience cluster in 2017’ launched by the BioIndustry Association and Informa Pharma Intelligence
25 January, 2018

The State of the Drug Discovery Nation Unveiled as New Report Provides Vital Insights for the Development of New Medicines

The Medicines Discovery Catapult and BioIndustry Association call on the R&D community to address five themes to help boost productivity
18 January, 2018

ZINPLAVA®? (bezlotoxumab) - a new therapy for the prevention of recurrence of Clostridium difficile infection - launched in the UK

Bezlotoxumab is the first EC licensed non-antibiotic option indicated to prevent Clostridium difficile infection (CDI) recurrence in high-risk adults
10 January, 2018

44% of Life Science Professionals Already Using or Experimenting with AI and Deep Learning, Finds Survey from The Pistoia Alliance

94% expect an increase in use of Machine Learning within two years, but access to quality data and technical expertise is a barrier to adoption
09 January, 2018

Nintedanib awarded Promising Innovative Medicine designation for malignant pleural mesothelioma with phase II trial showing progression-free survival benefit when added to first-line chemotherapy

Nintedanib has been designated a Promising Innovative Medicine for the treatment of malignant pleural mesothelioma (MPM) by the UK Medicine and Healthcare Products Regulatory Agency (MHRA). This is an early indication that the MHRA considers nintedanib a promising candidate for the Early Access to Medicines Scheme, which aims to give patients with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need
04 January, 2018

AstraZeneca and Imperial College London Establish Research Collaboration to Investigate Biological Drivers of Respiratory Disease

AstraZeneca and Imperial College London have announced a new research collaboration in respiratory disease which will see their scientists working side-by-side to investigate basic scientific mechanisms and underlying drivers of conditions such as asthma and chronic obstructive pulmonary disease (COPD).
02 January, 2018

News Archive